GlobalData on MSN18h
Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
FiercePharma1d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...
ENDPOINTS NEWS21h
Nek­tar di­vests man­u­fac­tur­ing site and reagent arm for $90M
Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...
Nektar to sell its Huntsville, Alabama facility to Ampersand Capital for $90M
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
bovnews15d
Uncover the Reason: Why Nektar Therapeutics (NKTR) Stock Is Trading 241.74% Above Its 52-Week Low?
On Friday, Nektar Therapeutics (NKTR) stock saw a decline, ending the day at $1.41 which represents a decrease of $-0.04 or -2.76% from the prior close of $1.45. The stock opened at $1.44 and touched ...
EurekAlert!13d
Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300
Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of ...
Roblox, Peloton upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that ...